Reduced risk of back pain following teriparatide treatment: A meta-analysis

Osteoporosis International

Volumn 17, Issue 2, 2006, Pages 273-280

  Nevitt, Michael C ^a   Chen, Peiqi ^b   Dore, Robin K ^c   Reginster, Jean Yves ^d   Kiel, Douglas P ^e,f   Zanchetta, Jose R ^g   Glass, Emmett V ^b   Krege, John H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e RESEARCH AND TRAINING INSTITUTE   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g Instituto de Investigaciones Metabolicas   (Argentina)

Author keywords

Alendronate; Back pain; Hormone replacement therapy; Osteoporosis; rhPTH 1 34; Teriparatide

Indexed keywords

ALENDRONIC ACID; HORMONE; PARATHYROID HORMONE[1-34];

ARTICLE; BACKACHE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HORMONE SUBSTITUTION; HUMAN; MULTIVARIATE ANALYSIS; OSTEOPOROSIS; PATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; VERTEBRA FRACTURE;

ADULT; AGED; AGED, 80 AND OVER; BACK PAIN; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SPINAL FRACTURES; TERIPARATIDE;

EID: 30144439980     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-005-2013-2     Document Type: Article

References (39)

1. Riggs BL, Melton LJ III (1995) The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17 [Suppl 5]:505S-511S
2. Melton LJ III, Lane AW, Cooper C, Eastell R, O'Fallon WM, Riggs BL (1993) Prevalence and incidence of vertebral deformities. Osteoporos Int 3:113-119
3. Clark S (2002) Osteoporosis - the disease of the 21st century? Lancet 359:1714
4. Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ III (1992) Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 7:221-227
5. Gold DT (1996) The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 18 [Suppl 3]:185S-189S
6. Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, Segal M, Genant HK, Cummings SR (1998) The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 128:793-800
7. Ismail AA, Cooper C, Felsenberg D, Varlow J, Kanis JA, Silman AJ, O'Neill TW (1999) Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European Vertebral Osteoporosis Study Group. Osteoporos Int 9:206-213
8. Ettinger B, Black DM, Nevitt MC, Rundle AC, Cauley JA, Cummings SR, Genant HK (1992) Contribution of vertebral deformities to chronic back pain and disability. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 7:449-456
9. Matthis C, Weber U, O'Neill TW, Raspe H (1998) Health impact associated with vertebral deformities: results from the European Vertebral Osteoporosis Study (EVOS). Osteoporos Int 8:364-372
10. Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, Kanis J (2000) Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 15:1384-1392
11. Silverman SL, Minshall ME, Shen W, Harper KD, Xie S (2001) The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum 44:2611-2619
12. Lyles KW, Gold DT, Shipp KM, Pieper CF, Martinez S, Mulhausen PL (1993) Association of osteoporotic vertebral compression fractures with impaired functional status. Am J Med 94:595-601
13. Mazanec DJ, Podichetty VK, Mompoint A, Potnis A (2003) Vertebral compression fractures: manage aggressively to prevent sequelae. Cleve Clin J Med 70:147-156
14. Edmond SL, Kiel DP, Samelson EJ, Kelly-Hayes M, Felson DT (2005) Vertebral deformity, back symptoms, and functional limitations among older women: The Framingham Study. Osteoporos Int 16:1086-1095
15. Ray NF, Chan JK, Thamer M, Melton LJ III (1997) Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 12:24-35
16. Gehlbach SH, Burge RT, Puleo E, Klar J (2003) Hospital care of osteoporosis-related vertebral fractures. Osteoporos Int 14:53-60
17. Finnern HW, Sykes DP (2003) The hospital cost of vertebral fractures in the EU: estimates using national datasets. Osteoporos Int 14:429-436
18. Lyles KW (1999) Management of patients with vertebral compression fractures. Pharmacotherapy 19:21S-24S
19. Lieberman IH, Dudeney S, Reinhardt MK, Bell G (2001) Initial outcome and efficacy of "kyphoplasty" in the treatment of painful osteoporotic vertebral compression fractures. Spine 26:1631-1638
20. Watts NB, Harris ST, Genant HK (2001) Treatment of painful osteoporotic vertebral fractures with percutaneous vertebroplasty or kyphoplasty. Osteoporos Int 12:429-437
21. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541
22. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437-1443
23. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077-2082
24. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352
25. Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 109:267-276
26. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645
27. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
28. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:4528-4535
29. Fujita T, Inoue T, Morii H, Morita R, Norimatsu H, Orimo H, Takahashi HE, Yamamoto K, Fukunaga M (1999) Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels. Osteoporos Int 9:296-306
30. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA (2003) The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9-17
31. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF (2005) Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762-1768
32. Ste-Marie LG, Scheele WH, Jasqui S, Schwartz SL, Pohl G, Gaich GA (2001) Effect of ly333334 [recombinant human parathyroid hormone (1-34), rhPTH(1-34)] on bone density when given to postmenopausal women receiving hormone replacement therapy (HRT). Program and abstracts. The Endocrine Society's 83rd Annual Meeting June 20-23, abstract #OR42-5, p 125
33. Genant HK, Mitlak B, Myers S, Wertz B, Wang O (2000) Radiographic fracture grade is related to clinical disease severity. Results from the rhpth (1-34) fracture prevention study. Arthritis Rheum 43 [Suppl 9]:S383
34. Genant HK, Halse J, Briney WG, Xie L, Glass EV, Krege JH (2005) The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Curr Med Res Opin 21:1027-1034
35. Nakajima A, Shimoji N, Shiomi K, Shimizu S, Moriya H, Einhorn TA, Yamazaki M (2002) Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34). J Bone Miner Res 17:2038-2047
36. Andreassen TT, Ejersted C, Oxlund H (1999) Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 14:960-968
37. Nevitt MC, Thompson DE, Black DM, Rubin SR, Ensrud K, Yates AJ, Cummings SR (2000) Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med 160:77-85
38. Musgrave DS, Vogt MT, Nevitt MC, Cauley JA (2001) Back problems among postmenopausal women taking estrogen replacement therapy: The Study of Osteoporotic Fractures. Spine 26:1606-1612
39. Brynhildsen JO, Bjors E, Skarsgard C, Hammar ML (1998) Is hormone replacement therapy a risk factor for low back pain among postmenopausal women? Spine 23:809-813